Volume : 08, Issue : 11, November – 2021
Title:
21.DEVELOPMENT AND VALIDATION FOR ESTIMATION OF CLINDAMYCIN, ADAPALENE AND SOFOSBUVIR IN BULK AND PHARMACEUTICAL DOSAGE FORMS BY RP-HPLC METHOD
Authors :
G. Swathi*, G.Deepthi , Deepthi Visakh, J. Prathyusha, Nafees Fatima, M. Sai lakshmi
Abstract :
A simple, accurate, rapid and precise isocratic stability indicating reversed-phase high-performance liquid chromatographic method has been developed and validated for simultaneous determination of Clindamycin and Adapalene in tablets. The chromatographic separation was carried out on C18 BDS Hypersil (150 x 4.6mm, 5µ) with a mixture ofmixed phosphate buffer : acetonitrile (55:45%v/v) as a mobile phase at a flow rate of 1.0mL/min. UV detection was performed at 230nm. The retention times were2.84 and 3.999min for Clindamycin and Adapalene respectively. Calibration plots were linear (r2=0.999) over the concentration range of 25-150µg/mL for Clindamycinand2.5-15µg/mL for Adapalene. The method was validated for accuracy, precision, specificity, linearity and sensitivity. The proposed method was successfully used for quantitative analysis of tablets. No interference from any component of pharmaceutical dosage form was observed. Validation studies revealed that method is specific, rapid, reliable, and reproducible. The high recovery and low relative standard deviation confirm the suitability of the method for routine determination of Clindamycin and Adapalene in bulk and tablet dosage form.
Sofosbuvir is used primarily to treat hepatitis C and viral hemorrhagic fevers. It is possible to select a sofosbuvir resistant mutant of HCV that can replicate to levels similar to wild type virus grown without sofosbuvir. Analysis of the mutations responsible for the sofosbuvir resistance may aid in understanding the mechanism of action of sofosbuvir.
Keywords: Clindamycin , Adapalene, RP-HPLC, Tablets, hepatitis C.
Cite This Article:
Please cite this article in press Gundeboina. Swathi et al, Development And Validation For Estimation Of Clindamycin , Adapalene And Sofosbuvir In Bulk And Pharmaceutical Dosage Forms By RP-HPLC Method., Indo Am. J. P. Sci, 2021; 08(11).
Number of Downloads : 10
References:
1. http://en.wikipedia.org/wiki/Melatonin.
2. http://en.wikipedia.org/wiki/Zolpidem.
3. Jhon Wiley and Sons ,Connors K A. A Textbook of Pharmaceutical Analysis. 3th Edn;1999, 196-198.
4. Skoog D A, West, D M, Holler, F J and Crouch S R. Fundamentals of Analytical chemistry. Thomson Brooks/Cole;8th Edn: 160-167.
5. R. Rühl, H. Nau Determination of adapalene (CD271/differin®) and retinol in plasma and tissue by on-line solid-phase extraction and HPLC analysis. Chromatographia1997, Volume 45, Issue 1, pp 269-274.
6. R. Mailvelan HPLC method development and validation for the estimation ofAdapalene in pharmaceutical formulations; in press. doi:10.3797/scipharm.1404-01.
7. Daniel J. Platzer , Brent A. WhiteDevelopment and validation of a gradient HPLC method for the determination of clindamycin and related compounds in a novel tablet formulation. Journal of Pharmaceutical and Biomedical AnalysisVolume 41, Issue 1, 11 April 2006, Pages 84–88.
8. Liu Li-ping HU Liu-jiang ZHOU Xiao-fen. HPLC determination of content and entrapment efficiency of adapalene liposomes. Chinese Journal of Pharmaceutical Analysis 2007-09.
9. Maliheh Barazandeh Tehran . Derivative spectrophotometric method for simultaneous determination of clindamycin phosphate and tretinoin in pharmaceutical dosage forms.. Journal of Chromatographic Science, Vol. 49, November/December 2011.
10. Yuerong Rose Ye, Edin Bektic, Richard Buchta, Robert Houlden andBarry Hunt.Simultaneous determination of tretinoin and clindamycin phosphate and their degradation products in topical formulations by reverse phase HPLC Journal of Separation Science Volume 27, Issue 1-2, pages 71–77, January 2004
11. ICH, Q2A, Text on Validation of Analytical Procedures, International Conference on
Harmonization, Geneva, October 1994, 1-5.
12. ICH, Q2B, Validation of Analytical Procedures: Methodology, International Conference on Harmonization, Geneva, November 1996, 1-8.
13. Moyer VA, on behalf of the U. S. Preventive Services Task Force Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med.2013;159(5):349–357.
14. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714.
15. Chak E, Talal AH, Sherman KE, et al. Hepatitis C virus infection in USA: An estimate of true prevalence.Liver Int. 2011;31:1090–1101.
16. Hoofnagle J, Di Bisceglie A. The treatment of chronic viral hepatitis. N Engl J Med. 1997;336:347–356. . McHutchison J, Gordon S, Schiff E, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485–1492.
17. . Poordad F, McCone JJ, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206.
18. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416.
19. Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients. Hepatology. 2009;50:1709–1718. [PubMed]
20. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007;132:1767–1777.
21. Sovaldi [package insert] Foster City, California: Gilead Sciences, Inc.; 2013.
22. Statement on a nonproprietary name adopted by the USAN Council.Accessed on May 3, 2013.
23. Lohmann V, Korner F, Herian U, Bartenschlager R. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J Virol. 1997;71(11):84
24. Sofia M, Bao D, Chang W, et al. Discovery of a β-D-2′-deoxy-2′-a-fluoro-2′-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 2010;53:7202–7218.
25. Murakami E, Tolstykh T, Bao H, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010;285(45):34337–34347.